Compare Citius Pharmaceuticals Inc (CTXR) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Tyson Foods, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Tyson Foods, Inc. trades at $53.43 (market cap $18.41B). The key difference: Tyson Foods, Inc. is far larger — about 1351.7× Citius Pharmaceuticals Inc's market cap, and Tyson Foods, Inc. pays a 3.9% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Tyson Foods, Inc. for 76 Days on average.
| CTXR | TSN | |
|---|---|---|
Market Cap | $13.62M | $18.41B |
Volume | 132,438 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $68.75 |
52-Week Low | $0.48 | $50.47 |
Typical Hold Time | 17 Days | 76 Days |
Enterprise Value | $3.79M | $25.68B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
Tyson Foods (TSN) trades at $53.43, up 3.35% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99, beating expectations, but faces challenges with thin 1.03% net margins and ongoing beef segment losses. Recent news highlights securities investigations and reduced 2026 revenue guidance, creating investor uncertainty despite institutional buying activity.
The stock presents a cautious opportunity with analyst consensus target of $65.40 (22% upside) but faces significant headwinds from margin pressure and legal scrutiny. Key risks include beef segment profitability, potential securities violations, and volatile cash flow patterns. Upside depends on operational improvements and resolution of ongoing investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
